Subsequently, we have shown that male gender, a large tumour volume, prolonged time to prolactin normalization and presence of a cystic, hemorrhagic and/or necrotic component (before the start of the pharmacological treatment) had an important contribution in the prediction of resistance to dopamine agonists in prolactinoma patients. Here, PRL is linked to neoplasm.